Novo Nordisk is a global healthcare company with 90 years of
and leadership in diabetes care. The company also has leading
within haemophilia care, growth hormone therapy and hormone
replacement therapy. Headquartered inDenmark, Novo Nordisk employs
approximately 354,000 employees in 75 countries, and markets its
products in more than 180 countries. Novo Nordisk’ s B shares
on NASDAQ OMXCopenhagen(Novo-B). Its ADRs are listed on the New
YorkStock Exchange (NVO).
Novo Nordisk international graduate program started from year2001 inheadquarters inDenmark.
The program launched all over the world in Novo Nordisk. It aims to grow young
talents with Novo Nordisk value and international mindset. The program is
consisting of two challenging assignments inChinaandDenmarkheadquarter which provides a broad platform to develop business knowledge,
working competencies and global mindset.